<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00595140</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT-Nr. 2007-005585-12</org_study_id>
    <secondary_id>EudraCT-Nr. 2007-005585-12</secondary_id>
    <nct_id>NCT00595140</nct_id>
  </id_info>
  <brief_title>Acute Application of Pegvisomant and Octreotide in Acromegaly</brief_title>
  <official_title>The Effect of Acute Application of Pegvisomant Alone and in Combination With Octreotide on Endogenous GH Levels During a 6 Hour Test in Patients With Acromegaly on Constant Pegvisomant Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the efficacy of an acute additional application of
      the somatostatin analogue octreotide 100µg s.c. or the dopamine agonist cabergoline 0.5mg
      p.o. to the receptor antagonist pegvisomant during a 6 or 9 hour profile on reducing
      endogenous growth hormone in patients with acromegaly on stable pegvisomant therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The decrease of endogenous growth hormone</measure>
    <time_frame>6 or 9 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The course of glucose, insulin and pegvisomant during the profiles</measure>
    <time_frame>6 or 9 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients with acromegaly on stable pegvisomant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with acromegaly on stable pegvisomant therapy and additional application of octreotide 100µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with acromegaly on stable pegvisomant therapy and additional application of cabergoline 0.5mg orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegvisomant</intervention_name>
    <description>growth hormone receptor antagonist pegvisomant in patients´ individual dose</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Pegvisomant:</other_name>
    <other_name>SOMAVERT 10 mg: EU/1/02/240/001</other_name>
    <other_name>SOMAVERT 15 mg: EU/1/02/240/002</other_name>
    <other_name>SOMAVERT 20 mg: EU/1/02/240/003</other_name>
    <other_name>SOMAVERT 20 mg: EU/1/02/240/004</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combination with somatostatin analogue octreotide</intervention_name>
    <description>s.c., 100µg, one time</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Octreotide: Sandostatin 100µg: MA number 29423.01.00</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combination with dopamine agonist cabergoline</intervention_name>
    <description>oral, 0.5mg, one time</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Cabergoline: Dostinex 0.5mg: MA number 32411.00.00</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with acromegaly currently on stable pegvisomant therapy

          -  patients with diabetes mellitus may be included. Glucose levels must be controlled
             regularly throughout the study

          -  patients must not be co-treated with any other medication for acromegaly

        Exclusion Criteria:

          -  radiotherapy within the last 2 years

          -  any relevant acute disease

          -  history of hypersensitivity against any of the used drugs

          -  pregnancy or lactation

          -  abnormal baseline findings
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Schopohl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Klinik - Innenstadt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Klinik - Innenstadt of the University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2008</study_first_submitted>
  <study_first_submitted_qc>January 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2008</study_first_posted>
  <last_update_submitted>March 31, 2008</last_update_submitted>
  <last_update_submitted_qc>March 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. Jochen Schopohl</name_title>
    <organization>Medizinische Klinik - Innenstadt of the University of Munich</organization>
  </responsible_party>
  <keyword>Acromegaly,</keyword>
  <keyword>growth hormone receptor antagonist,</keyword>
  <keyword>somatostatin analogue,</keyword>
  <keyword>combined medical treatment,</keyword>
  <keyword>acute effect,</keyword>
  <keyword>endogenous GH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Cabergoline</mesh_term>
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

